Results 151 to 160 of about 273,432 (244)

Microvascular dysfunction causing myocardial ischemia in obstructive hypertrophic cardiomyopathy. [PDF]

Radiol Case Rep
Theerasuwipakorn N, Montrivade S, Kosum P, Chattranukulchai P.   +3 more
europepmc   +1 more source

Treatment With Phosphodiesterase 5 Inhibitors and Long‐Term Outcomes in Patients Undergoing Coronary Angiography and Cardiac Catheterization

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background The effects of phosphodiesterase 5 (PDE5) inhibitors on the incidence of long‐term outcomes in patients with cardiovascular disease are not well understood. Objective: We studied the association between PDE5 inhibitor therapy and the incidence of adverse cardiovascular major adverse cardiovascular events (MACE) in patients ...
Sumon Roy, Annette Min, Edward O. McFalls, Robert A. Perera, Fadi N. Salloum, Ion S. Jovin   +5 more
wiley   +1 more source

Comprehensive evaluation of non-coding RNA-mediated autophagy regulation in myocardial ischemia-reperfusion injury. [PDF]

Front Pharmacol
Song Z, Suo C, Liu Y, Jin L, Xie X, Liu J, Yu B, Wang Y, Zhang Z, Xie D.   +9 more
europepmc   +1 more source

Overlap of Takayasu Arteritis and Kawasaki Disease in Infants

Chronic Diseases and Translational Medicine, EarlyView.
Echocardiography showed the myocardial ischemia presentation of an 8‐month‐old boy.
Jingya Li, Yan Sun, Liyuan Xu, Shanshan Li, Ning Ma   +4 more
wiley   +1 more source

Caveolin-3: therapeutic target for diabetic myocardial ischemia/reperfusion injury. [PDF]

Mol Med
Wen X, Ji Y, Tang H, Jin Z, Su W, Zhou L, Xia ZY, Li L, Lei S.   +8 more
europepmc   +1 more source

Enhancing WRAP‐Based Nanoparticles for Small Interfering Ribonucleic Acid Delivery in pH‐Sensitive Environments

ChemMedChem, EarlyView.
PEGylation of the WRAP5‐based nanoparticles via acyl hydrazone linkers is achieved to obtain a pH‐sensitive small interfering ribonucleic acid‐targeted delivery. In acidic extracellular conditions (pH 5) occurring during myocardial ischemia‐reperfusion injury, this optimized delivery system is the only one showing efficient silence of the Fas ...
Giulia Di Gregorio, Coélio Vallée, Karidia Konate, Clémentine A. Teko‐Agbo, Thania Hammoum, Héloïse Faure‐Gautron, Yannick Bessin, Sebastien Deshayes, Eric Vivès, Albano C. Meli, Pascal de Santa Barbara, Sandrine Faure, Stéphanie Barrère‐Lemaire, Sébastien Ulrich, Prisca Boisguérin   +14 more
wiley   +1 more source

Sex differences in cardiac dynamics during myocardial ischemia using a single cell approach. [PDF]

Sci Rep
Wei N.
europepmc   +1 more source

Impact of Age and Factor Xa Inhibitor Concentrations on Bleeding Risk in Patients with Atrial Fibrillation

Clinical Pharmacology &Therapeutics, EarlyView.
This study aimed to analyze differences in the exposure‐response relationship for factor Xa inhibitors (FXaI) between patients aged ≥ 80 and < 80 years. Patients with atrial fibrillation (AF) taking rivaroxaban, apixaban, or edoxaban were enrolled, and a single steady‐state trough concentration was measured.
Shin‐Yi Lin, Yen‐Bing Liu, Li‐Ting Ho, Ching‐Hua Kuo, Yu‐Fong Peng, Chih‐Fen Huang, Sung‐Chun Tang, Jiann‐Shing Jeng   +7 more
wiley   +1 more source

The Inhibition of Prolyl Endopeptidase (PREP) by KYP-2047 Treatment to Reduce Myocardial Ischemia/Reperfusion Injury. [PDF]

Antioxidants (Basel)
Cucinotta L, Palermo N, Ardizzone A, Capra AP, Campolo M, Esposito E, Casili G, Lanza M.   +7 more
europepmc   +1 more source

The nitrates and myocardial ischemia. [PDF]

Circulation, 1982
openaire   +3 more sources